<DOC>
	<DOCNO>NCT00668031</DOCNO>
	<brief_summary>The purpose study ass aprotinin ( BAY A0128 ) , give intravenously surgery , safe help reduce amount bleed need blood transfusion hip replacement surgery . Patients undergo major surgery risk significant blood loss . Because , need drug help slow amount bleed surgery .</brief_summary>
	<brief_title>Effect Aprotinin Transfusion Requirements Blood Loss Patients Undergoing Elective Primary Total Hip Replacement</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Aprotinin</mesh_term>
	<criteria>Subjects require elective primary total hip replacement surgery Documented , sign , date informed consent obtain prior study specific procedure perform Subjects previous exposure aprotinin last 6 month . If subject undergone cardiac surgery last 6 month , attempt make ascertain aprotinin administer cardiac surgery . If record available , subject exclude . If cardiac surgery last 6 month , record aprotinin administration , subject exclude Subjects know suspect allergy aprotinin Subjects impair renal function ( serum creatinine &gt; 3.5 mg/dl 309 micromoles/liter ) Subjects history bleed diathesis know coagulation factor deficiency Subjects failure major organ system active significant medical illness opinion investigator likely affect subject 's ability complete study precludes subject 's participation study Subjects refuse receive allogenic blood product religious reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Transfusion requirement</keyword>
	<keyword>Hip replacement surgery</keyword>
	<keyword>Prevention blood loss</keyword>
	<keyword>Bloodloss</keyword>
</DOC>